Children's Hospitals and Clinics of Minnesota Selects CDEX ValiMed(TM) to Implement Medication Validation Solution; ValiMed System Verifies Compounded Medications and Doses, and Validates Narcotic Returns
ROCKVILLE, Md. & MINNEAPOLIS, Apr 03, 2006 (BUSINESS WIRE) CDEX, Inc. (CEXI) announced today that Children's Hospitals and Clinics of Minnesota has selected the ValiMed(TM) system to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed medication verification system, which was developed by CDEX ( www.cdex-inc.com) and is exclusively distributed by Baxa ( www.baxa.com), gives clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded.
Children's of Minnesota is the eighth-largest children's health care organization in the U.S., with 319 staffed beds at its two hospital campuses in St. Paul and Minneapolis, Minnesota. An independent, not-for-profit health care system, Children's of Minnesota provides care through over 13,000 inpatient visits and more than 200,000 emergency room and other outpatient visits each year.
In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"At Children's, our top priority is the safety of our patients. With the ValiMed product we will enhance our patient and medication safety by verifying compounded medication and narcotic returns right in the pharmacy," said Christine Koentopp, Director of Pharmacy at Children's Hospitals and Clinics of Minnesota.
"We are pleased that Children's of Minnesota has joined a list of nationally recognized healthcare organizations that have adopted this new health safety measure, and is the first healthcare system in Minnesota to use ValiMed," said Jim Griffin, CEO for CDEX. "It is gratifying to see ValiMed being accepted as a life safety and quality control product by healthcare professionals across the nation. The number of prestigious healthcare organizations that are adopting ValiMed to verify compounded medications and doses, and validate narcotic returns continues to grow."
The ValiMed solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process. The ValiMed Medication Validation System is distributed under an exclusive agreement with Baxa Corporation ( www.baxa.com) of Englewood, Colorado.
About Children's Hospitals and Clinics of Minnesota
Children's of Minnesota has received national recognition for its work in patient safety, including a recent ranking as one of only eight pediatric hospitals among the "50 Exceptional U.S. Hospitals" by the Leapfrog Group, a consortium of 165 national employers that provide health coverage to 36 million employees. For more information about Children's of Minnesota, visit www.childrensmn.org.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.
SOURCE: CDEX, Inc.
